Kimberly-Clark completes US$48.7B Kenvue acquisition in according to the company.
Through a growing portfolio of baby care, women’s health, and active aging brands, the Kenvue acquisition fortifies Kimberly-Clark’s position to leverage this systems-level health care gap with its consumer products. The company is “well-positioned” to serve a global health and wellness industry that has reached over US$500 billion in spending annually, according to Kimberly-Clark.
The European Commission approved the acquisition subject to remedies aimed at addressing competition concerns in feminine hygiene. Kimberly-Clark committed to divesting its Kotex, Camelia, and Record brands in the European Economic Area, removing the overlap with Kenvue’s OB tampons.
Kimberly-Clark expects the Kenvue acquisition to generate US$2.1 billion in run-rate synergies.
Differentiated financial framework
Kimberly-Clark’s anticipated approximate US$2.1 billion run-rate synergies are made up of cost synergies and incremental profit. Cost synergies are approximated at US$1.9 billion and anticipated to be captured in the first three years following close. Incremental profit from revenue synergies is anticipated at US$500 million and partially offset by reinvestment of roughly US$300 million, captured within four years post-close.
Kimberly-Clark says that the company has “substantially built its pipeline of cost and revenue initiatives as part of a robust integration plan.”
The finalized deal comes as Kenvue posted its fourth consecutive quarter of net and organic sales growth in its Q3 2026 financials late last week.
The company saw strong performance in
White & Private Label Expo London 2026
China Import and Export Fair Complex Guangzhou
